Esperion Therapeutics (ESPR) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$32.0 million.
- Esperion Therapeutics' Income towards Parent Company fell 289.96% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 16011.92%. This contributed to the annual value of -$4.8 million for FY2024, which is 9773.98% up from last year.
- As of Q3 2025, Esperion Therapeutics' Income towards Parent Company stood at -$32.0 million, which was down 289.96% from -$13.4 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Income towards Parent Company registered a high of $58.2 million during Q1 2024, and its lowest value of -$90.9 million during Q1 2021.
- In the last 5 years, Esperion Therapeutics' Income towards Parent Company had a median value of -$51.6 million in 2023 and averaged -$42.9 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 19246.41% in 2024, then tumbled by 17129.71% in 2025.
- Over the past 5 years, Esperion Therapeutics' Income towards Parent Company (Quarter) stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then soared by 63.71% to -$20.8 million in 2024, then plummeted by 53.58% to -$32.0 million in 2025.
- Its last three reported values are -$32.0 million in Q3 2025, -$13.4 million for Q2 2025, and -$41.5 million during Q1 2025.